Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-495 single- and multiple-ascending dose study in healthy adults
jRCT2071250132Recruiting
- Sponsor
- Takeda
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Randomised, double-blind trial comparing TAK-495 with Placebo (2 arms). Primary endpoint: Number of participants with at least 1 treatment-emergent adverse event. Started Feb 2026; status: recruiting.
02
Drugs
TAK-495
Beyond the preview
Go deeper on jRCT2071250132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250132.